Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma
S Jagannath, CC Jackson, JM Schecter… - Expert Opinion on …, 2024 - Taylor & Francis
Introduction Ciltacabtagene autoleucel (cilta-cel), a BCMA-targeting CAR-T therapy, is
approved in the United States and Europe for patients with relapsed/refractory multiple …
approved in the United States and Europe for patients with relapsed/refractory multiple …
Cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma.
8030 Background: CARTITUDE-1 is a single arm study of Ciltacabtagene autoleucel (cilta-
cel; JNJ-68284528) anti-BCMA CAR-T cell therapy in US patients (pts) with relapsed …
cel; JNJ-68284528) anti-BCMA CAR-T cell therapy in US patients (pts) with relapsed …
Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years …
SZ Usmani, TG Martin, JG Berdeja, AJ Jakubowiak… - 2022 - ascopubs.org
8028 Background: Ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T (CAR-
T) cell therapy with 2 B-cell maturation antigen (BCMA)–targeting single-domain antibodies …
T) cell therapy with 2 B-cell maturation antigen (BCMA)–targeting single-domain antibodies …
CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.
8009 Background: Heavily pretreated patients (pts) with relapsed/refractory multiple
myeloma (RRMM) treated with standard of care therapy have median overall survival (OS) …
myeloma (RRMM) treated with standard of care therapy have median overall survival (OS) …
Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple …
NWCJ van de Donk, ME Agha, AD Cohen, YC Cohen… - 2022 - ascopubs.org
8029 Background: In cohort B of the multicohort phase 2 CARTITUDE-2 (NCT04133636)
study, the efficacy and safety of cilta-cel are being evaluated in patients (pts) with MM who …
study, the efficacy and safety of cilta-cel are being evaluated in patients (pts) with MM who …
Efficacy outcomes and characteristics of patients with multiple myeloma (MM) who achieved sustained minimal residual disease negativity after treatment with …
Introduction: Cilta-cel is a BCMA-targeting CAR T-cell therapy that was recently approved by
the US FDA for the treatment of adult patients (pts) with relapsed/refractory multiple myeloma …
the US FDA for the treatment of adult patients (pts) with relapsed/refractory multiple myeloma …
Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in lenalidomide (len)-refractory …
H Einsele, AD Cohen, M Delforge, J Hillengass… - 2022 - ascopubs.org
8020 Background: Cohort A of the multicohort phase 2 CARTITUDE-2 (NCT04133636)
study is evaluating cilta-cel safety and efficacy in pts with MM who received 1–3 prior LOT …
study is evaluating cilta-cel safety and efficacy in pts with MM who received 1–3 prior LOT …
[HTML][HTML] S202: cartitude-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma
N Munshi, T Martin, SZ Usmani, J Berdeja… - …, 2023 - journals.lww.com
Background: Heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM)
treated with standard of care therapy have median overall survival (OS) of~ 12 months. In …
treated with standard of care therapy have median overall survival (OS) of~ 12 months. In …
Ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE …
NWCJ Van De Donk, M Agha, AD Cohen, YC Cohen… - Blood, 2022 - ashpublications.org
Introduction: In cohort B of the multicohort phase 2 CARTITUDE-2 (NCT04133636) study,
the efficacy and safety of cilta-cel are being evaluated in patients with multiple myeloma …
the efficacy and safety of cilta-cel are being evaluated in patients with multiple myeloma …
Comparison of cilta-cel, an anti-BCMA CAR-T cell therapy, versus conventional treatment in patients with relapsed/refractory multiple myeloma
Background In the single-arm, phase 1b/2 CARTITUDE-1 study, ciltacabtagene autoleucel
(cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) …
(cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) …